DONGGUAN, CHINA - EQS Newswire -14 January 2020 - Recently, Great Bay Bio signed off convertible note, and the company will be injected with 2.5 million USD by existing shareholders, which including renowned financial institute and family foundation. Such injection of funds fully shows the confidence and support by existing shareholders to Great Bay Bio for its results in 2019. Capital will be injected into projects, to further optimize CMC service platform and product pipeline development of Great Bay Bio. Dr. Chen Liang, the CEO of Great Bay Bio, said: "Progress for Great Bay Bio projects has exceeded  expectations with remarkable results. We will continue putting our effort into projects in response to the affirmation and support of Great Bay Bio shareholders."

About Great Bay Bio

Headquarteredin Hong Kong, the CMC/CDMO platform of Great Bay Bio was established in 2002,where originally more than 100 million yuan was invested to build a nationallevel CMC platform. The CMC/CDMO platform has independent and integratedtechnology platforms for drug R&D and large scale preparation. The companyhas a strong existing track record of developing customized CMC packages forbiologic products, some of which are national class I projects of innovativebiological new drugs that have already reached NDA stage.

Greta Bay Biopositions itself as a Contract Development and Manufacturing Organization(CDMO), applying AI technology on CMC (Chemistry, Manufacturing, Control)platform for drug development, which targets the headache for recent drugdevelopment process including long development timeline and high developmentcost, and solves such headache with AI+CMC to enhance efficiency and reducecost. CMC technology platform runs AI analysis model with massive data out fromconventional biologics development, combining AI and biotechnology, so toovercome hurdle for biologics development and greatly reduce developmenttimeline and development cost. With such Great Bay Bio could provide muchcheaper, efficient and high-quality drug development service for clients, andalso brings much economical drug for society.

The platformhas been recognized and certificated as "Patent FosteringEnterprise", "Patent Pilot Enterprise", "National High-techEnterprise", "Dongguan New R&D Institution", "GuangdongTop Ten Foreign-funded R&D Center" and "Guangdong GeneticallyPharmaceutical Engineering Research Center". Since 2006, it has undertakena number of government projects and obtained crucial breakthroughs in key areasof Guangdong and Hong Kong. More than 20 million yuan have been received fromthe government to support numerous provincial and national projects, such as"National Major New Drug Innovation"

TheCMC platform encompasses an area of over 3100 square meter, and has a whole setof advanced biopharmaceutical research and development hardware, with keyequipment from world-class brands such as Sartorius, Bio-Rad, GE Healthcare,and Waters. The pilot workshop is designed strictly in accordance with cGMPrequirements, with cleanroom standards of C-level and partial A-level.